Amboy Street Ventures
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Amboy Street Ventures.
Key people at Amboy Street Ventures.
Key people at Amboy Street Ventures.
# Amboy Street Ventures: Pioneering Capital for Women's Health Innovation
Amboy Street Ventures is the world's first venture capital fund dedicated exclusively to women's health and sexual wellbeing across all genders[1]. Founded in 2020 and headquartered in Los Angeles, the firm targets the underserved $1 trillion global women's health market by investing in innovative startups addressing critical gaps in fertility, menopause, maternal health, LGBTQ+ health, menstruation, hormonal health, sexual health, and contraception[1].
The fund's investment philosophy centers on bridging a historical funding gap that has stunted innovation in women's and sexual health sectors[1]. Rather than deploying capital passively, Amboy Street Ventures operates as an active investor, providing portfolio companies with strategic support through its Value Enhancement Team, which assists with marketing, branding, sales, product development, scientific innovation, and public education[1]. The firm primarily focuses on Seed and Series A stage investments, backing companies advancing the industry across America and Europe[1].
Amboy Street Ventures was founded in 2020 by Carli Sapir, who leads the investment team and brings personal passion for women's health innovation[1]. The firm's name carries profound historical significance—it references the Amboy Street Birth Control Clinic in Brooklyn, which opened in 1916 as the first U.S. birth control clinic[5]. Margaret Sanger established this clinic to educate women on pregnancy prevention during an era when discussing contraception was illegal; she was arrested twice at the clinic before eventually founding Planned Parenthood[5].
This historical anchor reflects the founders' commitment to health equity and social reformation. The team assembled by Sapir includes partners with expertise spanning private equity, medicine, sexual health, and marketing[1]. The firm's emergence in 2020 was particularly well-timed—that year saw online searches for "sexual wellness" spike by 850 percent on major retailers during pandemic lockdowns, signaling growing consumer demand and cultural acceptance for these solutions[5].
Amboy Street Ventures operates in a category of one—no other venture capital fund globally maintains such singular dedication to women's health and sexual wellbeing. This specialization allows the firm to develop deep domain expertise and cultivate a concentrated network of founders, advisors, and industry experts within this ecosystem[1].
Beyond capital deployment, the firm's Value Enhancement Team provides hands-on operational support across critical functions including marketing, branding, sales, and product development[1]. This approach recognizes that many women's health startups face unique challenges in market education, regulatory navigation, and go-to-market strategy that require specialized guidance.
The fund's portfolio spans a remarkable breadth of health categories—from Evvy (vaginal microbiome testing), Contraline (non-hormonal male birth control), and HeyJane (digital abortion clinics) to Millie (modern maternity clinics), Gennev (menopause telehealth), and Allswell (LGBTQ+ therapy)[2]. This diversity demonstrates the firm's commitment to comprehensive health coverage rather than narrow specialization within women's health.
With multiple closed and active funds—including a fund that opened in July 2024—Amboy Street Ventures has demonstrated the ability to raise institutional capital for a thesis that was previously considered niche[4]. This validates both the market opportunity and the firm's execution capability.
Amboy Street Ventures operates at the intersection of several powerful macro trends. First, there's the normalization of sexual and reproductive health discourse—what was taboo a decade ago is now mainstream consumer conversation, particularly among younger demographics. The firm is capitalizing on this cultural shift by channeling venture capital into solutions that were previously starved of funding[5].
Second, the firm addresses a systemic capital allocation inefficiency. Women's health represents a $1 trillion market opportunity yet has historically received disproportionately small allocations from venture capital[1]. This gap reflects both investor bias and the challenge women founders face in fundraising for health categories perceived as niche. By creating a dedicated fund, Amboy Street Ventures is correcting a market failure and unlocking innovation that benefits society broadly.
Third, the firm is riding the digital health and direct-to-consumer healthcare wave. Many portfolio companies leverage telehealth, at-home testing, and consumer-friendly platforms to democratize access to services previously gatekept by traditional healthcare infrastructure. This aligns with broader healthcare transformation trends.
Finally, Amboy Street Ventures contributes to health equity and inclusive innovation. By explicitly serving all genders—including LGBTQ+ populations—the firm is expanding the definition of women's health beyond cisgender women, reflecting evolving medical and social understanding[1].
Amboy Street Ventures has established itself as a consequential player in reshaping how venture capital addresses historically underserved health markets. The firm's success will likely inspire similar thesis-driven funds focused on other neglected health categories, potentially fragmenting the venture landscape into more specialized, mission-aligned vehicles.
Looking ahead, the firm faces both opportunities and challenges. On the opportunity side, regulatory tailwinds—particularly around telehealth, at-home diagnostics, and reproductive health—will likely accelerate portfolio company growth. The normalization of sexual wellness as a consumer category suggests sustained demand tailwinds. On the challenge side, the firm must navigate complex regulatory environments, particularly around reproductive health, which varies dramatically by geography and political climate.
The most significant question for Amboy Street Ventures' future influence is whether it can scale beyond early-stage investing. As portfolio companies mature into Series B and beyond, the firm's ability to support growth-stage financing—or to facilitate follow-on rounds with larger institutional investors—will determine whether it becomes a true ecosystem anchor or remains primarily a seed-stage specialist.
Ultimately, Amboy Street Ventures represents a broader thesis: that venture capital's greatest opportunities often lie in correcting historical blind spots. By systematically investing in women's health innovation, the firm is not only building financial returns but reshaping how the startup ecosystem allocates resources toward human wellbeing.
